Genmab: nine-month revenue climbs 22% to $3.24 billion
Genmab's nine-month revenue rose 22% and adjusted operating profit grew 9%, while three positive Phase 3 readouts support potential 2027 launches.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, Genmab's revenue for the first nine months of 2026 reached $3,238 million, up 22%. Adjusted operating profit increased 9%, and the company described the growth as broad-based across its portfolio.
The company reported three positive Phase III readouts across its late-stage assets, which support potential launches in 2027. Its 2026 guidance remains unchanged. Priorities for 2027 include profit growth and gross leverage below 3x.
why it matters
For investors, the key points are steady guidance and a clearer late-stage pipeline. Positive Phase III data reduces uncertainty about future sales, though actual revenue will depend on regulatory approvals and how well the drugs sell after launch.
market impact
Genmab shares: revenue growth and successful trials support interest in the stock
- Genmab shares pressure up — revenue growth and positive Phase 3 data strengthen expectations for upcoming launches
tags
instruments
sources
- GMAB: 22% revenue growth and three positive Phase 3 readouts set up potential 2027 launches — TradingView, 5 November 2026 at 16:26 UTC
- GMAB: Broad-based growth and three positive phase III readouts set up the next growth phase — TradingView, 5 November 2026 at 19:20 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗